Cargando…

First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis

BACKGROUND: The current trial was a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the recombinant monoclonal anti−interleukin-20 (IL-20) antibody, NNC0109-0012, which targets the inflammatory cytokine IL-20. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gottlieb, Alice B., Krueger, James G., Sandberg Lundblad, Mia, Göthberg, Marie, Skolnick, Brett E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529098/ https://www.ncbi.nlm.nih.gov/pubmed/26252485 http://dx.doi.org/10.1371/journal.pone.0134703

Ejemplares similares

A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults
por: Niu, Suping, et al.
Publicado: (2022)

Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
por: Pangilinan, Mary Catherine G., et al.
Publicado: (2020)

Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis
por: Wada, Yumiko, et al.
Publicado: (2012)

Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis
por: Hsu, Yu-Hsiang, et al.
Publicado: (2016)

Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma
por: Chiu, Yi-Shu, et al.
Publicado: (2017)

Monitoring Appropriate Monoclonal Antibodies Prescribing via Administrative Data: An Application to Psoriasis
por: Guidotti, Elisa, et al.
Publicado: (2022)

Generation and diversification of recombinant monoclonal antibodies
por: DeLuca, Keith F, et al.
Publicado: (2021)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab
por: McKenzie, Andrew, et al.
Publicado: (2021)

Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study
por: Jiang, Congjun, et al.
Publicado: (2022)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
por: Rodríguez-Fernández, Karine, et al.
Publicado: (2022)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
por: Becerra, Carlos R., et al.
Publicado: (2014)

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
por: Denlinger, Crystal S., et al.
Publicado: (2021)

Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study
por: Torii, Hideshi, et al.
Publicado: (2016)

Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss
por: Hsu, Yu-Hsiang, et al.
Publicado: (2011)

Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models
por: Hsu, Yu-Hsiang, et al.
Publicado: (2015)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
por: Li, Qian, et al.
Publicado: (2022)

The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine
por: Jain, Saurabh, et al.
Publicado: (2016)

Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis
por: Anghel, Flavia, et al.
Publicado: (2021)

Anti CD-6 Monoclonal Antibodies in the Management of Generalised Pustular Psoriasis
por: Kura, Mahendra M., et al.
Publicado: (2022)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
por: Glatt, Sophie, et al.
Publicado: (2017)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

Anti-IL-20 monoclonal antibody inhibited inflammation and protected against cartilage destruction in murine models of osteoarthritis
por: Hsu, Yu-Hsiang, et al.
Publicado: (2017)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
por: Lenders, Malte, et al.
Publicado: (2022)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
por: Lassen, U, et al.
Publicado: (2012)

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
por: Boutros, Celine, et al.
Publicado: (2020)

Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody
por: Wang, Yan, et al.
Publicado: (2020)

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
por: COHN, ALLEN, et al.
Publicado: (2014)

Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis
por: Henderson, Robert D., et al.
Publicado: (2021)

First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers
por: Blank, Antje, et al.
Publicado: (2022)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Revisiting dose-finding of monoclonal antibodies in migraine
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bl1ldieknbet17lv5bqg7h3c12